Chardan Capital Forecasts Immuneering FY2025 Earnings

Immuneering Co. (NASDAQ:IMRX - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Immuneering in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings of ($1.65) per share for the year. Chardan Capital currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Immuneering's current full-year earnings is ($1.86) per share.

A number of other analysts have also recently weighed in on IMRX. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th. Needham & Company LLC restated a "buy" rating and set a $12.00 price target on shares of Immuneering in a research report on Friday, March 21st.

Immuneering Trading Down 0.3 %

IMRX traded down $0.01 on Thursday, hitting $1.64. 37,990 shares of the company's stock were exchanged, compared to its average volume of 1,776,107. The stock has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.02. Immuneering has a twelve month low of $1.00 and a twelve month high of $3.83. The firm has a market cap of $58.68 million, a PE ratio of -0.83 and a beta of -0.32.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16).

Institutional Trading of Immuneering

Several hedge funds have recently added to or reduced their stakes in the business. Corsair Capital Management L.P. acquired a new position in shares of Immuneering during the third quarter valued at $25,000. HighTower Advisors LLC grew its position in Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock valued at $132,000 after buying an additional 9,400 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in Immuneering during the 4th quarter valued at about $390,000. XTX Topco Ltd raised its position in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after buying an additional 20,871 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Immuneering in the 4th quarter worth approximately $47,000. Institutional investors own 67.65% of the company's stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.